Biogen

News

The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.

News

A study has suggested early targeting of amyloid in the brains of people with inherited Alzheimer's can delay symptoms, but not all are convinced.

News

An observational study backed by Biogen has suggested that Apple smartphones and watches may be able to spot the signs of mild cognitive impairment.

News

Eisai and Biogen have another chance to convince NICE that the NHS should cover the cost of Alzheimer's therapy Leqembi.

News

Eisai and Biogen have been unable to persuade Australia's medicines regulator to approve their Alzheimer's therapy Leqembi with a narrower label.

News

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics.